U.S. markets closed
  • S&P 500

    3,363.00
    +27.53 (+0.83%)
     
  • Dow 30

    27,781.70
    +329.04 (+1.20%)
     
  • Nasdaq

    11,167.51
    +82.26 (+0.74%)
     
  • Russell 2000

    1,507.69
    +2.96 (+0.20%)
     
  • Crude Oil

    39.93
    -0.29 (-0.72%)
     
  • Gold

    1,892.40
    -3.10 (-0.16%)
     
  • Silver

    23.43
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1734
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    0.6770
    +0.0320 (+4.96%)
     
  • GBP/USD

    1.2926
    +0.0066 (+0.51%)
     
  • USD/JPY

    105.4180
    -0.2370 (-0.22%)
     
  • BTC-USD

    10,758.55
    -85.66 (-0.79%)
     
  • CMC Crypto 200

    221.39
    -0.01 (-0.00%)
     
  • FTSE 100

    5,866.10
    -31.40 (-0.53%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®

Current IND for sarcoma paves the way for future INDs for late-stage prostate cancer

Noxopharm (ASX: NOX) announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Veyonda® for combination treatment with doxorubicin in patients with soft tissue sarcomas.

"Based on preclinical and clinical data, the FDA’s approval of this IND is validation of the clinical potential of Veyonda®," said Noxopharm CMO Gisela Mautner, M.D., Ph.D. "Further, it means that Veyonda® has met stringent FDA standards for safety and tolerability."

"While the Company’s resources and energies are primarily focused on bringing a treatment for late-stage prostate cancer to market, this IND grant for a less common cancer type advances that commercial objective," said Noxopharm CEO Graham Kelly, Ph.D. "The recent IND approval process has familiarized the FDA with Veyonda® ahead of IND applications for more advanced DARRT and LuPIN study submissions. It also opens the door to Veyonda®’s use in the U.S., where patient demand has been growing."

DARRT and LuPIN are ongoing investigations in which combination therapies with Veyonda® are exhibiting promising interim results for the treatment of late-stage, progressive prostate cancer resistant to other treatments.

"This IND grant is an important step toward achieving a strategic partnering arrangement," Kelly said. "With the emerging clinical data and growing evidence that Veyonda® is a uniquely acting immuno-oncology drug candidate designed to restore immune function to cold tumors, we are confident that the industry will recognize the considerable opportunities in the adjunctive benefits of Veyonda®."

Veyonda® is a suppository dosage form of idronoxil, a first-in-class inhibitor of sphingosine-1-phosphate (S1P). By inhibiting the overexpression of S1P-driven pro-survival pathways in solid tumors, idronoxil is designed to sensitize cancer cells to the anti-cancer effects of drugs such as doxorubicin, as well as to radiation.

About Noxopharm
Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX: NYR). Learn more at noxopharm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005215/en/

Contacts

Jane Byram
SCORR Marketing
(512) 626-2758
jane@scorrmarketing.com